Teva, OncoGenex 's Late-stage Trial Of Custirsen Fails

(RTTNews) - Teva Pharmaceutical Industries Ltd. (TEVA) and OncoGenex Pharmaceuticals, Inc. (OGXI) Monday said its Phase III SYNERGY trial of drug Custirsen in combination with First-line Docetaxel and Prednisone for Metastatic Castrate-Resistant Prostate Cancer or CRPC in men failed to meet primary endpoint. Custirsen is an experimental drug that is designed to block the production of the protein clusterin, which may play a fundamental role in cancer cell survival and treatment resistance.

The addition of custirsen to standard first-line docetaxel/prednisone therapy did not meet the primary endpoint of a statistically significant improvement in overall survival in men with metastatic CRPC, compared with docetaxel/prednisone alone.